{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:55:38Z","timestamp":1772726138813,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11010-024-05154-2","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:33:15Z","timestamp":1731598395000},"page":"2935-2949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PCSK9 and its relationship with HMGB1, TLR4, and TNF\u03b1 in non-statin and statin-treated coronary artery disease patients"],"prefix":"10.1007","volume":"480","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8477-5909","authenticated-orcid":false,"given":"Dina A.","family":"Desouky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-1963","authenticated-orcid":false,"given":"Nahla A.","family":"Nosair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7771-4402","authenticated-orcid":false,"given":"Mohamed K.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-9202","authenticated-orcid":false,"given":"Mohammed A.","family":"El-Magd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2625-3698","authenticated-orcid":false,"given":"Muhammad A.","family":"Desouky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-643X","authenticated-orcid":false,"given":"Dalia E.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"25","key":"5154_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al (2020) Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol 76(25):2982\u20133021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"5154_CR2","first-page":"1006","volume":"1","author":"EA El-Moselhy","year":"2018","unstructured":"El-Moselhy EA, Mohammed AS, Abd El-Aziz A, Sadek I, Hagrass SA, Farag GA (2018) Coronary artery disease among elderly Egyptian patients: I. socio-demographic, lifestyle, psychosocial, medical, and biochemical risk factors. Am J Gerentol Geriatr 1(2):1006","journal-title":"Am J Gerentol Geriatr"},{"issue":"5","key":"5154_CR3","first-page":"127","volume":"9","author":"T Levstek","year":"2022","unstructured":"Levstek T, Podkraj\u0161ek N, Rehberger Likozar A, \u0160ebe\u0161tjen M, Trebu\u0161ak PK (2022) The influence of treatment with PCSK9 inhibitors and variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) genes on the corresponding inflammatory markers in patients with very high lipoprotein (a) levels. J Cardiovas Dev Dis 9(5):127","journal-title":"J Cardiovas Dev Dis"},{"issue":"11","key":"5154_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.amjcard.2015.09.009","volume":"116","author":"H Gonz\u00e1lez-Pacheco","year":"2015","unstructured":"Gonz\u00e1lez-Pacheco H, Amezcua-Guerra LM, Vazquez-Rangel A, Mart\u00ednez-S\u00e1nchez C, P\u00e9rez-M\u00e9ndez O, Verdejo J et al (2015) Levels of high-density lipoprotein cholesterol are associated with biomarkers of inflammation in patients with acute coronary syndrome. Am J Cardiol 116(11):1651\u20131657","journal-title":"Am J Cardiol"},{"issue":"2","key":"5154_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154\u2013156","journal-title":"Nat Genet"},{"key":"5154_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","volume":"288","author":"M Ruscica","year":"2019","unstructured":"Ruscica M, Tokg\u00f6zo\u011flu L, Corsini A, Sirtori CR (2019) PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis 288:146\u2013155","journal-title":"Atherosclerosis"},{"issue":"5","key":"5154_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","volume":"24","author":"MD Shapiro","year":"2017","unstructured":"Shapiro MD, Fazio S (2017) PCSK9 and atherosclerosis\u2014lipids and beyond. J Atheroscler Thromb 24(5):462\u2013472","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"5154_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/jmg.2006.038356","volume":"43","author":"SE Humphries","year":"2006","unstructured":"Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK et al (2006) Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43(12):943\u2013949","journal-title":"J Med Genet"},{"issue":"3","key":"5154_CR9","doi-asserted-by":"publisher","first-page":"e023328","DOI":"10.1161\/JAHA.121.023328","volume":"11","author":"E Punch","year":"2022","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M (2022) Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 11(3):e023328","journal-title":"J Am Heart Assoc"},{"key":"5154_CR10","doi-asserted-by":"publisher","first-page":"763516","DOI":"10.3389\/fcvm.2022.763516","volume":"9","author":"NQ Wu","year":"2022","unstructured":"Wu NQ, Shi HW, Li JJ (2022) Proprotein convertase subtilisin\/kexin type 9 and inflammation: an updated review. Front Cardiovasc Med 9:763516","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"5154_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000442976","volume":"8","author":"JH Boyd","year":"2016","unstructured":"Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR (2016) Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J Innate Immun 8(2):211\u2013220","journal-title":"J Innate Immun"},{"issue":"2","key":"5154_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/biomedicines11020503","volume":"11","author":"AV Poznyak","year":"2023","unstructured":"Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Gutyrchik NA, Orekhov AN (2023) Proprotein convertase subtilisin\/kexin 9 as a modifier of lipid metabolism in atherosclerosis. Biomedicines 11(2):503","journal-title":"Biomedicines"},{"issue":"5","key":"5154_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0022-2275(20)42221-7","volume":"21","author":"MS Brown","year":"1980","unstructured":"Brown MS, Goldstein JL (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21(5):505\u2013517","journal-title":"J Lipid Res"},{"issue":"1","key":"5154_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","volume":"35","author":"CJ Vaughan","year":"2000","unstructured":"Vaughan CJ, Gotto AM Jr, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35(1):1\u201310","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"5154_CR15","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L et al (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24(8):1454\u20131459","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"5154_CR16","doi-asserted-by":"publisher","first-page":"e019525","DOI":"10.1161\/JAHA.120.019525","volume":"10","author":"N Kuyama","year":"2021","unstructured":"Kuyama N, Kataoka Y, Takegami M, Nishimura K, Harada-Shiba M, Hori M et al (2021) Circulating mature PCSK9 level predicts diminished response to statin therapy. J Am Heart Assoc 10(11):e019525","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"5154_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489\u20131499","journal-title":"N Engl J Med"},{"issue":"11","key":"5154_CR18","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1172\/JCI25482","volume":"115","author":"AE Mullick","year":"2005","unstructured":"Mullick AE, Tobias PS, Curtiss LK (2005) Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115(11):3149\u20133156","journal-title":"J Clin Invest"},{"key":"5154_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH et al (2017) New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway. Atherosclerosis 262:113\u2013122","journal-title":"Atherosclerosis"},{"issue":"28","key":"5154_CR20","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.2174\/1568026623666221017144734","volume":"22","author":"E Oikonomou","year":"2022","unstructured":"Oikonomou E, Tsaplaris P, Anastasiou A, Xenou M, Lampsas S, Siasos G et al (2022) Interleukin-1 in coronary artery disease. Curr Top Med Chem 22(28):2368\u20132389","journal-title":"Curr Top Med Chem"},{"key":"5154_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yjmcc.2014.02.012","volume":"72","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Yang X, Bian F, Wu P, Xing S, Xu G, Li W, Chi J, Ouyang C, Zheng T, Wu D (2014) TNF-\u03b1 promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-\u03baB and PPAR-\u03b3. J Mol Cell Cardiol 72:85\u201394","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"5154_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","volume":"35","author":"S Kaptoge","year":"2013","unstructured":"Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A et al (2013) Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 35(9):578\u2013589","journal-title":"Eur Heart J"},{"issue":"6","key":"5154_CR23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/ATVBAHA.111.225508","volume":"31","author":"S Devaraj","year":"2011","unstructured":"Devaraj S, Jialal I (2011) C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 31(6):1397\u20131402","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"5154_CR24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Investig 111(12):1805\u20131812","journal-title":"J Clin Investig"},{"issue":"11","key":"5154_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","volume":"78","author":"W Zhang","year":"2021","unstructured":"Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K et al (2021) High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis. J Am Coll Cardiol 78(11):1083\u20131094","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"5154_CR26","doi-asserted-by":"publisher","first-page":"e52081","DOI":"10.1371\/journal.pone.0052081","volume":"7","author":"M Andrassy","year":"2012","unstructured":"Andrassy M, Volz HC, Maack B, Schuessler A, Gitsioudis G, Hofmann N et al (2012) HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease. PLoS ONE 7(12):e52081","journal-title":"PLoS ONE"},{"key":"5154_CR27","doi-asserted-by":"publisher","first-page":"111555","DOI":"10.1016\/j.biopha.2021.111555","volume":"139","author":"A Wahid","year":"2021","unstructured":"Wahid A, Chen W, Wang X, Tang X (2021) High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomed Pharmacother 139:111555","journal-title":"Biomed Pharmacother"},{"key":"5154_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","volume":"40","author":"R Kang","year":"2014","unstructured":"Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L et al (2014) HMGB1 in health and disease. Mol Aspects Med 40:1\u2013116","journal-title":"Mol Aspects Med"},{"issue":"4","key":"5154_CR29","doi-asserted-by":"publisher","first-page":"e100084","DOI":"10.1136\/gpsych-2019-100084","volume":"32","author":"H Zhang","year":"2019","unstructured":"Zhang H, Ding L, Shen T, Peng D (2019) HMGB1 involved in stress-induced depression and its neuroinflammatory priming role: a systematic review. General Psychiatry 32(4):e100084","journal-title":"General Psychiatry"},{"issue":"3","key":"5154_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.carpath.2006.11.006","volume":"16","author":"K Inoue","year":"2007","unstructured":"Inoue K, Kawahara KI, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I (2007) HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16(3):136\u2013143","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"5154_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/ATVBAHA.120.315517","volume":"41","author":"X Zhang","year":"2021","unstructured":"Zhang X, Fern\u00e1ndez-Hernando C (2021) Endothelial HMGB1 (High-Mobility Group Box 1) regulation of LDL (Low-Density Lipoprotein) transcytosis: a novel mechanism of intracellular HMGB1 in atherosclerosis. Arterioscler Thromb Vasc Biol 41(1):217\u2013219","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"5154_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","volume":"22","author":"P Roy","year":"2022","unstructured":"Roy P, Orecchioni M, Ley K (2022) How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol 22(4):251\u2013265","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"5154_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nri3671","volume":"14","author":"F Ginhoux","year":"2014","unstructured":"Ginhoux F, Jung S (2014) Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol 14(6):392\u2013404","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"5154_CR34","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","volume":"116","author":"L Ziegler-Heitbrock","year":"2010","unstructured":"Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN et al (2010) Nomenclature of monocytes and dendritic cells in blood. Blood 116(16):e74\u2013e80","journal-title":"Blood"},{"issue":"1","key":"5154_CR35","doi-asserted-by":"publisher","first-page":"e12883","DOI":"10.1111\/sji.12883","volume":"92","author":"A O\u017ca\u0144ska","year":"2020","unstructured":"O\u017ca\u0144ska A, Szymczak D, Rybka J (2020) Pattern of human monocyte subpopulations in health and disease. Scand J Immunol 92(1):e12883","journal-title":"Scand J Immunol"},{"issue":"1","key":"5154_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.4630","volume":"238","author":"I Giunzioni","year":"2016","unstructured":"Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S (2016) Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol 238(1):52\u201362","journal-title":"J Pathol"},{"issue":"1","key":"5154_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-020-01009-4","volume":"19","author":"Y Tang","year":"2020","unstructured":"Tang Y, Li SL, Hu JH, Sun KJ, Liu LL, Xu DY (2020) Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovasc Diabetol 19(1):33","journal-title":"Cardiovasc Diabetol"},{"key":"5154_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"ESC\/EAS guidelines for the management of dyslipidaemias","year":"2019","unstructured":"ESC\/EAS guidelines for the management of dyslipidaemias (2019) Lipid modification to reduce cardiovascular risk. Atherosclerosis 290:140\u2013205","journal-title":"Atherosclerosis"},{"issue":"3","key":"5154_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacl.2021.02.005","volume":"15","author":"KA Krychtiuk","year":"2021","unstructured":"Krychtiuk KA, Lenz M, Hohensinner P, Distelmaier K, Schrutka L, Kastl SP et al (2021) Circulating levels of proprotein convertase subtilisin\/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. J Clin Lipidol 15(3):512\u2013521","journal-title":"J Clin Lipidol"},{"issue":"3","key":"5154_CR40","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1002\/jcp.27254","volume":"234","author":"ZH Tang","year":"2019","unstructured":"Tang ZH, Li TH, Peng J, Zheng J, Li TT, Liu LS et al (2019) PCSK9: A novel inflammation modulator in atherosclerosis? J Cell Physiol 234(3):2345\u20132355","journal-title":"J Cell Physiol"},{"issue":"1","key":"5154_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s43088-024-00515-8","volume":"13","author":"DA Desouky","year":"2024","unstructured":"Desouky DA, Nosair NA, Sherif DE, El-Magd MA, Salama MK (2024) Association between circulatory microRNA-218 expression, serum PCSK9 levels, inflammatory markers, and monocyte subsets in coronary artery disease patients: impact of statin therapy. Beni-Suef Univ J Basic Appl Sci 13(1):52","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"issue":"2","key":"5154_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","volume":"220","author":"N Ferri","year":"2012","unstructured":"Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S et al (2012) Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 220(2):381\u2013386","journal-title":"Atherosclerosis"},{"issue":"9","key":"5154_CR43","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1089\/ars.2014.6054","volume":"22","author":"Z Ding","year":"2015","unstructured":"Ding Z, Liu S, Wang X, Deng X, Fan Y, Sun C et al (2015) Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal 22(9):760\u2013771","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"5154_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.atherosclerosis.2015.05.019","volume":"241","author":"A Edsfeldt","year":"2015","unstructured":"Edsfeldt A, Grufman H, Asciutto G, Nitulescu M, Persson A, Nilsson M et al (2015) Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis 241(2):443\u2013449","journal-title":"Atherosclerosis"},{"issue":"1","key":"5154_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cellimm.2012.09.008","volume":"279","author":"SS Yang","year":"2012","unstructured":"Yang SS, Li R, Qu X, Fang W, Quan Z (2012) Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells. Cell Immunol 279(1):96\u2013102","journal-title":"Cell Immunol"},{"issue":"5","key":"5154_CR46","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","volume":"118","author":"KL Wong","year":"2011","unstructured":"Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH et al (2011) Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118(5):e16-31","journal-title":"Blood"},{"issue":"5","key":"5154_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.hjc.2019.04.012","volume":"60","author":"F H\u00f6pfner","year":"2019","unstructured":"H\u00f6pfner F, Jacob M, Ulrich C, Russ M, Simm A, Silber RE, Girndt M, Noutsias M, Werdan K, Schlitt A (2019) Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. the PHAMOS trial (Prospective Halle Monocytes Study). Hellenic J Cardiol 60(5):311\u2013321","journal-title":"Hellenic J Cardiol"},{"issue":"25","key":"5154_CR48","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371(25):2383\u20132393","journal-title":"N Engl J Med"},{"issue":"5","key":"5154_CR49","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/HCO.0000000000000211","volume":"30","author":"HK Siddiqi","year":"2015","unstructured":"Siddiqi HK, Kiss D, Rader D (2015) HDL-cholesterol and cardiovascular disease: rethinking our approach. Curr Opin Cardiol 30(5):536\u2013542","journal-title":"Curr Opin Cardiol"},{"issue":"23","key":"5154_CR50","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","volume":"143","author":"A Rohatgi","year":"2021","unstructured":"Rohatgi A, Westerterp M, Av E, Remaley A, Rye K-A (2021) HDL in the 21st century: a multifunctional roadmap for future HDL research. Circulation 143(23):2293\u20132309","journal-title":"Circulation"},{"issue":"1","key":"5154_CR51","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/j.atherosclerosis.2015.04.356","volume":"241","author":"Y Nekaies","year":"2015","unstructured":"Nekaies Y, Baudin B, Sakly M, Attia N (2015) Plasma proprotein convertase subtilisin\/kexin type 9 (PCSK9) is associated with Lp(a) in type 2 diabetic patients. Atherosclerosis 241(1):e102","journal-title":"Atherosclerosis"},{"issue":"1","key":"5154_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-019-0233-y","volume":"17","author":"KAA Fox","year":"2020","unstructured":"Fox KAA, Metra M, Morais J, Atar D (2020) The myth of \u2018stable\u2019 coronary artery disease. Nat Rev Cardiol 17(1):9\u201321","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"5154_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1373\/clinchem.2011.176800","volume":"58","author":"A Khera","year":"2012","unstructured":"Khera A (2012) Statins, plasma proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL lowering. Clin Chem 58(1):6\u20137","journal-title":"Clin Chem"},{"issue":"03","key":"5154_CR54","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1160\/th15-08-0620","volume":"115","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, Bittner V, Ray KK, Watts GF, Hovingh GK, Rysz J (2016) The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thromb Haemost 115(03):520\u2013532","journal-title":"Thromb Haemost"},{"issue":"1","key":"5154_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352(1):29\u201338","journal-title":"N Engl J Med"},{"issue":"2","key":"5154_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1006\/phrs.2001.0922","volume":"45","author":"I Zelvyte","year":"2002","unstructured":"Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002) Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45(2):147\u2013154","journal-title":"Pharmacol Res"},{"issue":"2","key":"5154_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"K Koushki","year":"2021","unstructured":"Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY et al (2021) Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol 60(2):175\u2013199","journal-title":"Clin Rev Allergy Immunol"},{"key":"5154_CR58","unstructured":"Yin YX, Yao YM, Liu RM, Zhai HX, Li L, Zhang JJ, et al. (2010) [The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 22(5):306-8"},{"issue":"6","key":"5154_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/aps.2013.8","volume":"34","author":"M Liu","year":"2013","unstructured":"Liu M, Yu Y, Jiang H, Zhang L, Zhang PP, Yu P et al (2013) Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-\/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin 34(6):830\u2013836","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"5154_CR60","doi-asserted-by":"publisher","first-page":"e52081","DOI":"10.1371\/journal.pone.0052081","volume":"7","author":"M Andrassy","year":"2012","unstructured":"Andrassy M, Volz HC, Schuessler A, Gitsioudis G, Hofmann N, Laohachewin D et al (2012) HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease. PLoS ONE 7(12):e52081","journal-title":"PLoS ONE"},{"issue":"1","key":"5154_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cca.2009.06.016","volume":"406","author":"X Hu","year":"2009","unstructured":"Hu X, Jiang H, Bai Q, Zhou X, Xu C, Lu Z et al (2009) Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 406(1):139\u2013142","journal-title":"Clin Chim Acta"},{"issue":"2","key":"5154_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","volume":"41","author":"HD Jang","year":"2020","unstructured":"Jang HD, Lee SE, Yang J, Lee HC, Shin D, Lee H et al (2020) Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9. Eur Heart J 41(2):239\u2013252","journal-title":"Eur Heart J"},{"issue":"6","key":"5154_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1995-7645(13)60081-4","volume":"6","author":"DZ Shen","year":"2013","unstructured":"Shen DZ, Xin SL, Chen C, Liu T (2013) Effect of atorvastatin on expression of TLR4 and NF-\u03baB p65 in atherosclerotic rabbits. Asian Pac J Trop Med 6(6):493\u2013496","journal-title":"Asian Pac J Trop Med"},{"issue":"16","key":"5154_CR64","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jacc.2012.07.019","volume":"60","author":"KS Rogacev","year":"2012","unstructured":"Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P et al (2012) CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 60(16):1512\u20131520","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"5154_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.4630","volume":"238","author":"I Giunzioni","year":"2016","unstructured":"Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y et al (2016) Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol 238(1):52\u201362","journal-title":"J Pathol"},{"issue":"10","key":"5154_CR66","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S K\u00fchnast","year":"2014","unstructured":"K\u00fchnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V et al (2014) Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]. J Lipid Res 55(10):2103\u20132112","journal-title":"J Lipid Res"},{"issue":"1\u20133","key":"5154_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12026-012-8297-3","volume":"53","author":"KL Wong","year":"2012","unstructured":"Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC (2012) The three human monocyte subsets: implications for health and disease. Immunol Res 53(1\u20133):41\u201357","journal-title":"Immunol Res"},{"issue":"52","key":"5154_CR68","doi-asserted-by":"publisher","first-page":"e2426","DOI":"10.1097\/MD.0000000000002426","volume":"94","author":"JJ Li","year":"2015","unstructured":"Li JJ, Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, Qing P, Gao Y, Sun J, Liu G (2015) Proprotein convertase subtilisin\/kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study. Medicine 94(52):e2426","journal-title":"Medicine"},{"issue":"5","key":"5154_CR69","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/joim.12946","volume":"286","author":"J Rannikko","year":"2019","unstructured":"Rannikko J, Jacome Sanz D, Ortutay Z, Seiskari T, Aittoniemi J, Huttunen R et al (2019) Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality. J Intern Med 286(5):553\u2013561","journal-title":"J Intern Med"},{"key":"5154_CR70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.hjc.2021.05.002","volume":"63","author":"J Wang","year":"2022","unstructured":"Wang J, Han P, Gao M, Xiao J, Li X, Zhang N et al (2022) Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). Hellenic J Cardiol 63:22\u201331","journal-title":"Hellenic J Cardiol"},{"issue":"5","key":"5154_CR71","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","volume":"8","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, Li JJ (2014) Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 8(5):494\u2013500","journal-title":"J Clin Lipidol"},{"issue":"1","key":"5154_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12944-022-01672-4","volume":"21","author":"LS Silva-Berm\u00fadez","year":"2022","unstructured":"Silva-Berm\u00fadez LS, Vargas-Villanueva A, S\u00e1nchez-Vallejo CA, Palacio AC, Buitrago AF, Mendivil CO (2022) Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study. Lipids Health Dis 21(1):61","journal-title":"Lipids Health Dis"},{"issue":"6","key":"5154_CR73","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","volume":"37","author":"B Gencer","year":"2016","unstructured":"Gencer B, Montecucco F, Nanchen D, Carbone F, Klingenberg R, Vuilleumier N et al (2016) Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J 37(6):546\u2013553","journal-title":"Eur Heart J"},{"issue":"5","key":"5154_CR74","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/07853890.2015.1042908","volume":"47","author":"S Li","year":"2015","unstructured":"Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ et al (2015) Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med 47(5):386\u2013393","journal-title":"Ann Med"},{"issue":"3","key":"5154_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11883-024-01189-4","volume":"26","author":"S Surma","year":"2024","unstructured":"Surma S, Sahebkar A, Banach M (2024) Correction to: whether and why do we need a vaccine against atherosclerosis? can we expect it anytime soon? Curr Atheroscler Rep 26(3):73","journal-title":"Curr Atheroscler Rep"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05154-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:03:39Z","timestamp":1746191019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05154-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5154"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05154-2","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by Kafrelsheikh University\u2019s ethical committee (Approval Code: MKSU 50-3-5). The 2013 World Medical Association Helsinki Declaration\u2019s ethical guidelines were met by the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients who participated in the study gave their written consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}